Zhejiang Haisen Pharmaceutical Co., Ltd. – FDA 483, Apr 11, 2018
Zhejiang Haisen Pharmaceutical Co., Ltd., an Active Pharmaceutical Ingredient manufacturer, was cited for two significant observations during an FDA inspection. The firm demonstrated issues with data integrity, specifically inconsistencies between validation reports and raw data, and a lack of authenticity review for submitted data. Additionally, the company failed to adequately record, document, and investigate customer complaints in a timely manner, indicating deficiencies in their quality system.
ID · b0f2eebb-c102-4599-9f9a-419e15fab306
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.